Medtronic (MDT) CEO Geoffrey Martha Sells $4.8M of Stock

Medtronic plc Chairman and CEO Geoffrey Martha sold 50,000 shares of the medical device maker on October 15, 2026. The transaction was disclosed in a Form 4 filing with the SEC. The sale was executed under a pre-arranged trading plan at a price of $95.00 per share, for a total value of $4.75 million.

Inside Geoffrey Martha's Medtronic Trade

The Chief Executive Officer parted with 50,000 shares in a planned move on October 15, 2026. The shares changed hands at $95.00 apiece, bringing the total transaction value to $4.75 million. The stock closed at $95.45 on the day of the sale.

Other Institutional Activity in Medtronic plc

Patriot Financial Group Insurance Agency grew its holdings by 9,976 shares, ending with 49,893 shares worth about $4,305,290. Traphagen Investment Advisors took a new stake by adding 2,361 shares valued at about $203,704. Summit Financial Strategies also opened a new position with 2,327 shares worth about $200,797. Meanwhile, Massachusetts Financial Services Co. trimmed its position by 1,564,940 shares to hold 19,872,600 shares valued at about $1,882,928,850, and Deutsche Bank AG reduced its stake by 552,983 shares to finish with 18,449,877 shares worth about $1,748,125,845.

Medtronic plc Stock Down 1.0%

The medical device maker recently traded around $94.46, sitting 1.0% below its event closing price and 28.9% above its 52-week low. The company has a market value of $121.2 billion and a price-to-earnings ratio of 23.28.

Recent Earnings

Medtronic generated $37.5 billion in trailing-twelve-month revenue with earnings of $4.07 per share. The company reports its next financial results on November 17, 2026.

Dividend

Investors receive an annual dividend rate of $2.88 per share, which translates to a 3.02% dividend yield based on recent trading levels. The payout accounts for 70.0% of company earnings.

Insider Buying and Selling at Medtronic plc

Other corporate insiders also made moves prior to the CEO's transaction. Officer Harry Skip Kiil sold 4,189 shares for $336,965 on June 8, 2026, and later sold another 1,483 shares worth $138,883 on September 16, 2026. Officer Matthew R. Walter sold 3,102 shares at $83.15 per share for a total of $257,931 on July 8, 2026.

Analysts Set New Price Targets

Wall Street firms have adjusted their views on the healthcare company across recent weeks. On September 2, 2026, Truist Securities reiterated its hold rating while lifting its target to $99.0 from $86.0. UBS maintained a buy rating on September 3, 2026, raising its target to $110.0 from $100.0. TD Cowen kept a buy rating on September 30, 2026, holding its target steady at $110.0. Barclays initiated coverage with an equal-weight rating and a $95.0 target on October 7, 2026. BTIG maintained a buy rating on October 12, 2026, while adjusting its target to $99.0 from $100.0. Across the broader analyst community, the stock carries a consensus buy recommendation from 25 covering opinions with a mean price target of $104.4.

About Medtronic plc

Medtronic plc builds device-based medical therapies and technologies for hospitals, physicians, and patients around the globe. Operating out of Galway, Ireland, the firm focuses on cardiovascular care, neuroscience equipment, and surgical products to support clinical treatment worldwide.

Bottom Line

Insiders frequently execute sales through pre-arranged plans to manage personal portfolios without touching market operations. Investors will look toward the upcoming earnings release on November 17, 2026, for further updates on financial performance.